Compare Duke Energy Corp (DUK) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duke Energy Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Duke Energy Corp trades at $123.62 (market cap $96.05B), while State Street SPDR S&P Biotech ETF trades at $158.97. The key difference: Duke Energy Corp pays a 3.52% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Duke Energy Corp nearer its low. Which is the better fit depends on your goals.
| DUK | XBI | |
|---|---|---|
Market Cap | $96.05B | — |
Sector | Utilities | Broad Market / Factor |
52-Week High | $133.46 | $164.28 |
52-Week Low | $113.99 | $86.92 |
Enterprise Value | $188.56B | — |
Dividend Yield | 3.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $122.97, up 1.46% today, with a bearish technical signal but strong fundamentals. Recent earnings beat estimates for three consecutive quarters, with Q2 2026 EPS at $1.43 versus $1.30 expected. The company maintains solid profitability, with a net income margin of 15.78% and ROE of 10.01%. Cash flow trends show consistent operational strength, though investing outflows remain high due to infrastructure spending.
The outlook is mixed: analyst consensus is a Buy with a $136.17 price target, but technical indicators signal near-term caution. Key risks include regulatory scrutiny and high debt levels, while opportunities lie in data-center demand growth and dividend stability. Investors should weigh strong fundamentals against bearish technicals and macroeconomic headwinds.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
